{"id":9763,"date":"2025-03-28T03:07:03","date_gmt":"2025-03-28T02:07:03","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=9763"},"modified":"2025-03-28T03:07:10","modified_gmt":"2025-03-28T02:07:10","slug":"pfizer-is-it-a-value-play-or-past-its-prime","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/","title":{"rendered":"Pfizer: Is It a Value Play or Past Its Prime?"},"content":{"rendered":"<\/p>\n<p>Dive into the dynamic realm of <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/income-stock-comparison-pfizer-vs-altria-group\/\">Pfizer<\/a><\/b> <span class=\"ticker\" data-id=\"204972\">(NYSE: PFE)<\/span> with insights from our expert analysts in this engaging episode of the Motley Fool Scoreboard. Watch the video below to uncover critical market trends, valuable insights, and potential investment opportunities that could shape your portfolio!<br \/><em data-renderer-mark=\"true\">*Stock prices referenced were as of Feb. 19, 2025. The video was published on March 27, 2025.<\/em><\/p>\n<\/p>\n<p><em><strong>Wondering where to strategically invest $1,000 today?<\/strong> Our dedicated analyst team has unveiled what they consider to be the <strong><a href=\"https:\/\/oxfordwisefinance.com\/blog\/best-mens-gifts-at-kohls-top-5-picks\/\">10 best stocks<\/a><\/strong> to invest in right now. <span style=\"text-decoration: underline\"><strong><a href=\"https:\/\/oxfordwisefinance.com\/blog\/fico-stock-is-it-overvalued-or-a-great-investment\/\">Discover More \u00bb<\/a><\/strong><\/span><\/em><\/p>\n<\/p>\n<h2>Is Now the Right Time to Invest $1,000 in Pfizer?<\/h2>\n<p>Prior to making a stock purchase in <b>Pfizer<\/b>, it&#8217;s essential to evaluate this critical information:<\/p>\n<p>The <em>Motley Fool Stock Advisor<\/em> analyst team recently identified what they deem to be the <strong>10 best stocks<\/strong> for investors to consider right now, and notably, <b>Pfizer<\/b> did not make the list. The selected 10 stocks are projected to generate impressive returns in the years ahead, making them attractive options for savvy investors.<\/p>\n<p><strong><span style=\"font-weight: 400\">Take, for example, when <b>Nvidia<\/b> was included in this list on April 15, 2005&#8230; if you had invested $1,000 at that time based on our recommendation, <strong>you\u2019d now have $697,245<\/strong><span><strong><\/strong>!*<\/span><\/span><\/strong><\/p>\n<p>The <em>Stock Advisor<\/em> service offers investors a straightforward roadmap for achieving financial success. This includes comprehensive guidance on effective portfolio building, regular updates from seasoned analysts, and two fresh stock picks each month. Since its inception in 2002, the <em>Stock Advisor<\/em> service has remarkably <strong><span style=\"font-weight: 400\"><span>more than quadrupled<\/span><\/span><\/strong><strong><span style=\"font-weight: 400\"><span><\/span><\/span><\/strong> the returns of the S&amp;P 500 index. <strong><span style=\"font-weight: 400\">Ensure you don\u2019t miss out on the latest top 10 list by joining <em>Stock Advisor<\/em> today!<\/span><\/strong><\/p>\n<p><strong>View the 10 stocks now \u00bb<\/strong><\/p>\n<p><em><\/em><\/p>\n<p><em><em><span style=\"color: #767676;font-size: 8pt\">*Stock Advisor returns as of March 24, 2025<\/span><\/em><\/em><\/p>\n<\/p>\n<p><em>Karl Thiel holds positions in <b>Pfizer<\/b>. Keith Speights also has positions in <b>Pfizer<\/b>. The Motley Fool maintains positions in and recommends <b>Pfizer<\/b>. The Motley Fool adheres to a strict disclosure policy.<\/em><\/p>\n<p><a href=\"https:\/\/www.fool.com\/investing\/2025\/03\/27\/pfizer-value-play-or-past-its-prime\/?source=askdougpancakes&amp;utm_source=chromefollow&amp;utm_medium=feed&amp;utm_campaign=news&amp;referring_guid=984d9f8e-e702-475c-876b-5fd75902992e\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dive into the dynamic realm of Pfizer (NYSE: PFE) with insights from [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9764,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142,239],"tags":[],"class_list":["post-9763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","category-stock-analysis","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"Dive into the dynamic realm of Pfizer (NYSE: PFE) with insights from [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T02:07:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-28T02:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Pfizer: Is It a Value Play or Past Its Prime?\",\"datePublished\":\"2025-03-28T02:07:03+00:00\",\"dateModified\":\"2025-03-28T02:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/\"},\"wordCount\":310,\"commentCount\":3,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1\",\"articleSection\":[\"Finance &amp; Business\",\"Stock Analysis\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/\",\"name\":\"Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1\",\"datePublished\":\"2025-03-28T02:07:03+00:00\",\"dateModified\":\"2025-03-28T02:07:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/pfizer-is-it-a-value-play-or-past-its-prime\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer: Is It a Value Play or Past Its Prime?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/","og_locale":"en_US","og_type":"article","og_title":"Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance","og_description":"Dive into the dynamic realm of Pfizer (NYSE: PFE) with insights from [&hellip;]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-03-28T02:07:03+00:00","article_modified_time":"2025-03-28T02:07:10+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Pfizer: Is It a Value Play or Past Its Prime?","datePublished":"2025-03-28T02:07:03+00:00","dateModified":"2025-03-28T02:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/"},"wordCount":310,"commentCount":3,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","articleSection":["Finance &amp; Business","Stock Analysis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/","url":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/","name":"Pfizer: Is It a Value Play or Past Its Prime? - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","datePublished":"2025-03-28T02:07:03+00:00","dateModified":"2025-03-28T02:07:10+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/pfizer-is-it-a-value-play-or-past-its-prime\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Pfizer: Is It a Value Play or Past Its Prime?"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pfizer-Value-Play-or-Past-Its-Prime.jpg?fit=1280%2C720&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=9763"}],"version-history":[{"count":2,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9763\/revisions"}],"predecessor-version":[{"id":9766,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9763\/revisions\/9766"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/9764"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=9763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=9763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=9763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}